ReviewFEMS microbiology ecology2014
Gut microbiota-based translational biomarkers to prevent metabolic syndrome via nutritional modulation.
Review in FEMS microbiology ecology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 58 citations in OpenAlex.
- Short-term high fat diet-induced metabolic endotoxemia in older individuals with obesity: a randomized crossover study.The American journal of clinical nutrition · 2025Trial
- Associations of serum indolepropionic acid, a gut microbiota metabolite, with type 2 diabetes and low-grade inflammation in high-risk individuals.Nutrition & diabetes · 2018Trial
- Markers of systemic exposures to products of intestinal bacteria in a dietary intervention study.European journal of nutrition · 2016Trial
- Association of Circulating Protein Biomarkers of Gut Barrier Integrity and Inflammation with Colorectal Adenomas and Colorectal Cancers.Digestive diseases and sciences · 2026Article
- Oral-gut microbiome dysbiosis in obese smokers reveals compartment-specific shifts.AMB Express · 2026Article
- Exploring compositional and predicted functional alterations of gut microbiota in H. pylori infection.Scientific reports · 2025Article
- Triple-Probiotic-Fermented Goji (Microorganisms · 2025Article
- Novel perspectives on the link between obesity and cancer risk: from mechanisms to clinical implications.Frontiers of medicine · 2024Review
- Review
- Associations of non-traditional cardiovascular risk factors and body mass index with metabolic syndrome in the Chinese elderly population.Diabetology & metabolic syndrome · 2023Article
- The effect ofArchives of medical science : AMS · 2022Review
- 'Bouncing Back' From Subclinical Malaria: Inflammation and Erythrocytosis After Resolution ofFrontiers in immunology · 2022Article
- Positive influence of gut microbiota on the effects of Korean red ginseng in metabolic syndrome: a randomized, double-blind, placebo-controlled clinical trial.The EPMA journal · 2021Article
- The Role of Gut Barrier Dysfunction and Microbiome Dysbiosis in Colorectal Cancer Development.Frontiers in oncology · 2021Review
- Gut Microbiota: The Missing Link BetweenFrontiers in endocrinology · 2021Review
- Widespread protein lysine acetylation in gut microbiome and its alterations in patients with Crohn's disease.Nature communications · 2020Article
- The Targeted Impact of Flavones on Obesity-Induced Inflammation and the Potential Synergistic Role in Cancer and the Gut Microbiota.Molecules (Basel, Switzerland) · 2020Review
- Early Programming of Adult Systemic Essential Hypertension.International journal of molecular sciences · 2020Review
- The polyphenol-rich extract from chokeberry (Nutrition & metabolism · 2020Article
- Comparison of Bioinformatics Pipelines and Operating Systems for the Analyses of 16S rRNA Gene Amplicon Sequences in Human Fecal Samples.Frontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the face of the global epidemic of metabolic syndrome (MetS) and its strong association with the increasing rate of cardiovascular morbidity and mortality, it is critical to detect MetS at an early stage in the clinical setting to implement preventive intervention long before the complications arise. Lipopolysaccharide, the cell wall component of Gram-negative bacteria produced from diet-disrupted gut microbiota, has been shown to induce metabolic endotoxemia, chronic low-grade inflammation, and ultimately insulin resistance. Therefore, ameliorating the inflammation and insulin resistance underlying MetS by gut microbiota-targeted, dietary intervention has gained increasing attention. In this review, we propose using dynamic monitoring of a set of translational biomarkers related with the etiological role of gut microbiota, including lipopolysaccharide binding protein (LBP), C-reactive protein (CRP), fasting insulin, and homeostasis model assessment of insulin resistance (HOMA-IR), for early detection and prevention of MetS via nutritional modulation. LBP initiates the recognition and monomerization of lipopolysaccharide and amplifies host immune responses, linking the gut-derived antigen load and inflammation indicated by the plasma levels of CRP. Fasting plasma insulin and HOMA-IR are measured to evaluate insulin sensitivity that is damaged by pro-inflammatory cytokines. The dynamic monitoring of these biomarkers in high-risk populations may provide translational methods for the quantitative and dynamic evaluation of dysbiosis-induced insulin resistance and the effectiveness of dietary treatment for MetS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.